1. Home
  2. AMGN vs WFC Comparison

AMGN vs WFC Comparison

Compare AMGN & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$437.81

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Logo Wells Fargo & Company

WFC

Wells Fargo & Company

N/A

Current Price

$79.06

Market Cap

248.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AMGN
WFC
Founded
1980
1852
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
251.6B
248.2B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
AMGN
WFC
Price
$437.81
$79.06
Analyst Decision
Hold
Buy
Analyst Count
34
27
Target Price
★ $435.77
$97.38
AVG Volume (30 Days)
2.1M
★ 7.9M
Earning Date
11-03-2026
10-13-2026
Dividend Yield
2.30%
★ 2.48%
EPS Growth
★ 88.23
16.57
EPS
★ 14.79
5.47
Revenue
$25,424,000,000.00
★ $85,063,000,000.00
Revenue This Year
$7.45
$5.36
Revenue Next Year
$4.54
$5.34
P/E Ratio
$29.67
★ $14.74
Revenue Growth
★ 8.83
N/A
52 Week Low
$312.39
$72.78
52 Week High
$483.99
$97.76

Technical Indicators

Market Signals
Indicator
AMGN
WFC
Relative Strength Index (RSI) 41.75 33.03
Support Level $338.02 $77.95
Resistance Level $446.42 $83.70
Average True Range (ATR) 11.75 2.10
MACD -4.96 -0.70
Stochastic Oscillator 4.16 2.20

Price Performance

Historical Comparison
AMGN
WFC

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

About WFC Wells Fargo & Company

Wells Fargo is a premier, North American-focused banking titan that commands a $2.25 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,079 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.

Share on Social Networks: